secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001628280-25-009785
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex reports record Q4 net sales $29.1M (+37% YoY); first full-year net income $8.6M
--------------------------------------------------------------------------------

- Full-year net sales $99.6M (+19% YoY); Tru Niagen sales $76.8M (+10%), Niagen ingredients $19.2M (+82%).
- Q4 net income $7.2M vs $0.1M a year ago; full-year net income $8.6M vs net loss $4.9M in 2023.
- Adjusted EBITDA $8.5M in 2024; operating cash flow $12.1M; cash $44.7M with no debt.
- G&A expense dropped $6.6M for the year due to $3.5M royalty reversal and $1.3M legal settlement recovery.
- FDA granted Orphan Drug and Rare Pediatric Disease Designations for NR; Niagen Plus now at 475+ clinics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828025009785/0001628280-25-009785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828025009785/cdxc-20250304.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-009785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer